CANbridge Pharmaceuticals (HKG: 1228) has announced that its Phase II clinical study for CAN008 (asunercept) in newly diagnosed glioblastoma multiforme (GBM) did not achieve progression-free survival (PFS) or overall survival (OS) benefits. As a result, the Sino-US biopharma company has decided to discontinue the development of CAN008 for GBM.
The resources saved from this decision will be redirected towards the commercialization of approved products Hunterase (idursulfase-beta) and Livmarli (maralixibat), as well as clinical studies for other pipeline candidates. This includes CAN106, which is currently in a Phase 1b study for paroxysmal nocturnal hemoglobinuria, and CAN103, which is in registration studies for Gaucher’s disease.
Asunercept is a CD95-Fc fusion protein that inhibits the interaction between the CD95 ligand and its receptor. It has a unique dual mechanism of action, blocking the invasive growth and migration of tumor cells while reducing T-cell apoptosis, thus enhancing immune recognition of cancer.- Flcube.com
